Another private equity giant makes a big move into biotech as Apollo executes €1B play — while life sci stocks shrivel
Private equity is making more big inroads into the biotech scene. And Antoine Papiernik and the crew at Sofinnova Partners are getting a substantial boost in the money they have available to invest in biotech.
The European VC says that the $32 billion private equity player Apollo Global Management $APO has stepped up to take a minority stake in the life sci player, offering €1 billion of managed capital to its funds.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.